Cellectar Biosciences (CLRB) Projected to Post Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) is expected to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Cellectar Biosciences to post earnings of ($1.8850) per share and revenue of $8.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last posted its earnings results on Wednesday, March 4th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.66. On average, analysts expect Cellectar Biosciences to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cellectar Biosciences Stock Up 26.9%

NASDAQ:CLRB traded up $0.76 on Tuesday, reaching $3.59. The company’s stock had a trading volume of 50,916,908 shares, compared to its average volume of 650,851. Cellectar Biosciences has a 12-month low of $2.43 and a 12-month high of $20.60. The firm has a market cap of $15.23 million, a price-to-earnings ratio of -0.37 and a beta of 0.43. The stock has a 50 day moving average price of $2.92 and a 200 day moving average price of $3.22.

Institutional Investors Weigh In On Cellectar Biosciences

A number of institutional investors have recently modified their holdings of CLRB. Bank of America Corp DE grew its stake in shares of Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 41,704 shares in the last quarter. DRW Securities LLC grew its stake in Cellectar Biosciences by 114.2% during the 4th quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 24,089 shares in the last quarter. Citadel Advisors LLC acquired a new position in Cellectar Biosciences during the 3rd quarter worth $104,000. Dimensional Fund Advisors LP acquired a new position in Cellectar Biosciences during the 3rd quarter worth $73,000. Finally, XTX Topco Ltd acquired a new position in Cellectar Biosciences during the 4th quarter worth $36,000. 16.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cellectar Biosciences in a research note on Tuesday. Maxim Group raised Cellectar Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cellectar Biosciences currently has an average rating of “Hold” and a consensus target price of $11.00.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.